Latest Monoclonal antibodies Stories
-- Anti-EphA3 Agents Inhibit Tumor Growth by Disrupting or Destroying the Tumor Microenvironment: Malignant Stem Cells, Stromal Cells, and New Tumor Vasculature -- SOUTH SAN FRANCISCO, Calif.,
SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Lpath, Inc.
SAN DIEGO, Aug. 8, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
Leukotuximab is a novel, first-in-class Leukemia-specific mAb targeting JL-1 SHENYANG, China, Aug.
Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August
MONROVIA, Calif., Aug. 5, 2014 /PRNewswire/ -- Xencor, Inc.
TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
The factors contributing to sample preparation market growth are the improvements in the funding scenario globally, increase in the number of government sponsored research activities, and developments
- To swell, as grain or wood with water.
More Images (1 images) »